vTv Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

• vTv Therapeutics Inc VTVT.OQ reported a quarterly adjusted loss of 55 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of $-1.67. The lone analyst forecast for the quarter was for a loss of 87 cents per share.

• Revenue was $17.00 thousand​; analysts expected zero.

• vTv Therapeutics Inc's reported EPS for the quarter was a loss of 55 cents​.

• The company reported a quarterly loss of $3.63 million.

• vTv Therapeutics Inc shares had risen by 32.2% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts was unchanged in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for vTv Therapeutics Inc is $35.00

This summary was machine generated from LSEG data March 20 at 10:04 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)